NASDAQ:CELC Celcuity (CELC) Stock Price, News & Analysis $49.50 +0.28 (+0.57%) Closing price 04:00 PM EasternExtended Trading$49.52 +0.02 (+0.05%) As of 05:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Celcuity Stock (NASDAQ:CELC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Celcuity alerts:Sign Up Key Stats Today's Range$47.81▼$49.5850-Day Range$39.17▼$62.5352-Week Range$7.57▼$63.06Volume833,995 shsAverage Volume651,186 shsMarket Capitalization$2.10 billionP/E RatioN/ADividend YieldN/APrice Target$56.50Consensus RatingModerate Buy Company Overview Celcuity, Inc. is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors. Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways. These assays are intended to serve as companion diagnostics, guiding the use of therapies such as PARP inhibitors and other targeted molecules in oncology. In addition to its core diagnostic offerings, Celcuity collaborates with pharmaceutical companies to co-develop new companion tests alongside emerging drug candidates, aiming to streamline clinical development and regulatory approval. Headquartered in Malvern, Pennsylvania, Celcuity was founded in the mid-2000s by a team of scientists and clinicians with extensive experience in cancer biology and diagnostic innovation. The company’s operations are primarily focused on the North American market, where it provides testing services through its CAP-accredited and CLIA-registered laboratory. Celcuity’s leadership team brings together expertise in biopharma partnerships, clinical diagnostics, and regulatory affairs to advance its pipeline of precision oncology solutions.AI Generated. May Contain Errors. Read More Celcuity Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreCELC MarketRank™: Celcuity scored higher than 47% of companies evaluated by MarketBeat, and ranked 612th out of 942 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingCelcuity has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 5 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialCelcuity has a consensus price target of $56.50, representing about 15.1% upside from its current price of $49.10.Amount of Analyst CoverageCelcuity has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Celcuity's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Celcuity are expected to decrease in the coming year, from ($2.62) to ($3.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Celcuity is -14.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Celcuity is -14.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCelcuity has a P/B Ratio of 15.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Celcuity's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.83% of the outstanding shares of Celcuity have been sold short.Short Interest Ratio / Days to CoverCelcuity has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Celcuity has recently increased by 4.45%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCelcuity does not currently pay a dividend.Dividend GrowthCelcuity does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted13.83% of the outstanding shares of Celcuity have been sold short.Short Interest Ratio / Days to CoverCelcuity has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Celcuity has recently increased by 4.45%, indicating that investor sentiment is decreasing. News and Social Media3.1 / 5News Sentiment0.60 News SentimentCelcuity has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Celcuity this week, compared to 3 articles on an average week.Search Interest25 people have searched for CELC on MarketBeat in the last 30 days. This is an increase of 525% compared to the previous 30 days.MarketBeat Follows5 people have added Celcuity to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Celcuity insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,818,744.00 in company stock.Percentage Held by Insiders15.78% of the stock of Celcuity is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions63.33% of the stock of Celcuity is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Celcuity's insider trading history. Receive CELC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Celcuity and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CELC Stock News HeadlinesCelcuity: Blink And You Missed ItOctober 8 at 12:06 PM | seekingalpha.com3 Growth Companies With High Insider Ownership Seeing Up To 63% Revenue GrowthOctober 1, 2025 | finance.yahoo.comU.S. Government Blocked NVIDIA’s Buyout… Here’s WhyThe U.S. government doesn't normally block billion-dollar tech deals. But when NVIDIA tried to acquire this tiny supplier, the FTC slammed the door. Why?October 8 at 2:00 AM | Behind the Markets (Ad)Celcuity Inc. (CELC)’s FDA NDA for Gedatolisib Accepted Under RTOR, Accelerating ReviewOctober 1, 2025 | msn.comCelcuity, Inc. (NASDAQ:CELC) Receives Consensus Recommendation of "Buy" from AnalystsSeptember 27, 2025 | americanbankingnews.comGuggenheim starts Celcuity with Buy on breast cancer potentialSeptember 23, 2025 | msn.comCelcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) CongressSeptember 22, 2025 | globenewswire.comCelcuity’s breast cancer drug sends share price soaringSeptember 16, 2025 | msn.comSee More Headlines CELC Stock Analysis - Frequently Asked Questions How have CELC shares performed this year? Celcuity's stock was trading at $13.09 at the beginning of the year. Since then, CELC stock has increased by 275.1% and is now trading at $49.0950. How were Celcuity's earnings last quarter? Celcuity, Inc. (NASDAQ:CELC) announced its earnings results on Thursday, August, 14th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.90) by $0.14. Read the conference call transcript. When did Celcuity IPO? Celcuity (CELC) raised $18 million in an initial public offering on Wednesday, September 20th 2017. The company issued 2,000,000 shares at $8.00-$10.00 per share. Craig-Hallum Capital Group served as the underwriter for the IPO. How do I buy shares of Celcuity? Shares of CELC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Celcuity own? Based on aggregate information from My MarketBeat watchlists, some other companies that Celcuity investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Palo Alto Networks (PANW) and ServiceNow (NOW). Company Calendar Last Earnings8/14/2025Today10/08/2025Next Earnings (Estimated)11/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryHealthcare Current SymbolNASDAQ:CELC CIK1603454 Webwww.celcuity.com Phone(763) 392-0767FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Price Target for Celcuity$56.50 High Price Target$70.00 Low Price Target$30.00 Potential Upside/Downside+14.8%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($3.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$111.78 million Net MarginsN/A Pretax MarginN/A Return on Equity-150.07% Return on Assets-64.67% Debt Debt-to-Equity Ratio2.24 Current Ratio4.58 Quick Ratio4.58 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.11 per share Price / Book15.83Miscellaneous Outstanding Shares42,430,000Free Float35,732,000Market Cap$2.09 billion OptionableOptionable Beta0.70 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:CELC) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingThe warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gol...StockEarnings | SponsoredAn Early Move On The Next Shift In CoinLitecoin is already processing 500,000+ daily transactions, integrated with PayPal and Revolut, and now one fi...Market Tactic | Sponsored"I'm risking my reputation on this"If I'm right about what's coming, this could be the most important book you'll read this yearCrypto 101 Media | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredU.S. Government Blocked NVIDIA’s Buyout… Here’s WhyThe U.S. government doesn't normally block billion-dollar tech deals. But when NVIDIA tried to acquire this...Behind the Markets | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celcuity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celcuity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.